查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371970

2030 年頭孢菌素市場預測：按生成、類型、給藥途徑、配銷通路管道、劑型、用途、最終用戶和地區進行的全球分析

Cephalosporin Market Forecasts to 2030 - Global Analysis By Generation, Type, Route of Administration, Distribution Channel, Dosage Form, Application and End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球頭孢菌素市場規模為 160 億美元，預計預測期內年複合成長率為 5.3%，到 2030 年將達到 229.7 億美元。

頭孢菌素是一種廣譜殺菌 B-內醯胺抗生素，最初是從真菌頂孢菌中開發出來的。用於治療扁桃腺炎、支氣管炎、中耳炎、淋病、肺炎等細菌性疾病，以及皮膚感染疾病、鏈球菌咽頭炎、金黃色葡萄球菌感染疾病等。它抑制敏感細菌的細胞壁酶並抑制細胞合成。頭孢菌素主要用於預防和治療細菌引起的感染疾病。

根據2017年呼吸系統疾病全球影響報告，下呼吸道感染和肺炎是兩大死因，每年約400萬人死亡。 2015年，有920,136名5歲以下兒童死於肺炎，佔該年齡層所有死亡人數的15%。肺炎鏈球菌是 5 歲以下兒童肺炎最常見的細菌原因，2015 年罹患了393,000 名兒童。

感染疾病流行率不斷上升

頭孢菌素類抗生素廣泛用於治療多種細菌感染疾病。感染疾病的增加是由多種要素造成的。主要要素之一是抗藥性細菌的出現，例如抗甲氧西林金黃色葡萄球菌（MRSA）和超廣譜BETA-內醯胺酶（ESBL）產生者。這些抗藥性菌株很難用常規抗生素治療，增加了對許多這些細菌仍然有效的頭孢菌素抗生素的需求。此外，人口成長、都市化和旅遊增加等要素也導致感染疾病的傳播。隨著越來越多的人住得更近、更頻繁，感染疾病傳播的風險也旅遊增加。這創造了一個競爭的市場形勢，為醫療保健專業人員提供了多種頭孢菌素製劑。

高成本

頭孢類抗生素的高成本是市場的主要抑制因素。由於複雜的製造流程、研發成本以及嚴格的品管措施，頭孢菌素類抗生素常以高價出售。這些高成本可能會限制這些重要抗生素的獲取，特別是在低收入地區和醫療保健預算有限的地區。此外，頭孢菌素的高成本對醫療保健系統造成負擔，導致醫療支出增加。因此，這個要素阻礙了市場的成長。

增加在各醫療領域的用途

將頭孢菌素的用途擴展到其傳統用途之外，為各個醫學領域帶來了重大機會。頭孢菌素以其抗菌特性而聞名，在獸醫、農業和非臨床等多個領域的效用日益廣泛。在獸醫學中，頭孢菌素用於治療動物的細菌感染疾病，解決對動物健康和抗生素抗藥性細菌可能傳播給人類的擔憂。在農業領域，人們正在研究頭孢菌素在預防和治療農作物和牲畜細菌感染方面的潛力。這些用途旨在透過控制植物和動物的細菌性疾病來提高農業生產力並確保食品安全。此外，頭孢菌素也針對非臨床目的進行了研究，例如微生物合成過程和實驗室研究，證明了這種抗生素類別的多功能性超出了傳統的治療用途。這些不同的領域正在推動市場的擴張。

缺乏熟練的專業人員

由於缺乏熟練的專業人員，頭孢菌素市場面臨重大威脅。頭孢菌素抗生素需要製造、品管和給藥方面的專業知識。然而，缺乏具備處理這些業務所需技能和知識的專業人員。這種短缺影響了整體市場的生產力和效率，並可能導致藥物開發、製造和分銷的延遲。此外，我們滿足頭孢菌素類抗生素不斷成長的需求的能力可能有限，特別是在感染疾病高發生率地區。因此，它成為市場需求的主要障礙。

COVID-19 的影響

COVID-19病毒的爆發對頭孢菌素市場產生了重大負面影響。 COVID-19 帶來的封鎖、旅遊限制和企業倒閉影響了許多國家的經濟和部門。眾多工廠和工廠的關閉對國際市場上商品的生產、交付和銷售產生了不利影響。幾家公司已經警告可能會出現交貨延遲並減少未來的產品銷售。從確診病例和死亡人數來看，美國、印度、巴西、俄羅斯、法國、英國、土耳其、義大利和西班牙是受影響最嚴重的國家。

在預測期內，呼吸道感染疾病領域預計將是最大的。

由於全球呼吸道感染疾病患病不斷上升，呼吸道感染疾病（RTI）領域估計佔最大佔有率。頭孢菌素是一種抗生素，廣泛用於治療呼吸道感染疾病，包括肺炎、支氣管炎和鼻竇。它對多種細菌有效，包括肺炎鏈球菌和流感嗜血桿菌等常見呼吸道病原體，使其成為臨床醫生的首選。此外，抗藥性細菌的出現進一步強調了頭孢菌素在治療這些感染疾病中的重要性。類似這樣的持續配合措施預計將維持 RTI領域的成長。

第一代頭孢菌素細分市場預計在預測期內年複合成長率最高

預計第一代頭孢菌素細分市場在預測期內將出現良好成長。這些抗生素屬於早期頭孢菌素，對革蘭氏陽性菌（包括葡萄球菌和鏈球菌）具有廣譜活性。它常用於治療常見感染疾病，如皮膚和軟組織感染疾病、尿道感染和呼吸道感染疾病。此外，第一代頭孢菌素抗生素因其功效、相對成本和經過驗證的安全性而受到醫療保健相關人員的高度重視。它在市場上的長期存在和良好的實績使其成為可靠的選擇，特別是對於併發症的感染疾病。因此，該領域的成長需求正在增加。

佔比最高的地區

在估計期間，亞太地區佔據最大的市場佔有率。亞太地區是全球頭孢菌素市場的主要參與者。頭孢菌素是一類重要的抗生素，在該地區廣泛用於治療多種細菌感染疾病，包括呼吸道感染疾病、尿道感染以及皮膚和軟組織感染疾病。此外，中國、印度、日本、韓國等東南亞國家擁有完善的製藥產業，並積極致力於研發，高效創新生產頭孢類藥物。該地區的經濟成長和醫療保健支出的增加進一步推動了頭孢菌素類抗生素的需求，確保了強勁且充滿希望的市場前景。

複合年複合成長率最高的地區：

預計北美在預測期內將實現盈利成長。北美地區在全球頭孢菌素市場中佔據重要地位，是製藥進步和醫療保健基礎設施的主要中心。市場成長的推動要素包括細菌感染疾病患病的增加、更容易感染疾病的老年人口的增加以及對高效醫療保健解決方案的高需求。此外，美國和加拿大等國家在北美頭孢菌素市場處於領先地位。這些國家已經建立了藥品製造能力，並積極進行旨在技術創新和藥物研發的研發。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球頭孢菌素市場：按世代

  • 第一代頭孢菌素
  • 第二代頭孢菌素
  • 第三代頭孢菌素
  • 第四代頭孢菌素
  • 第五代頭孢菌素

第6章 全球頭孢菌素市場：依類型

  • 品牌
  • 通用的

第7章 全球頭孢菌素市場：依給藥途徑

  • 靜脈
  • 口服

第8章 全球頭孢菌素市場：依配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 全球頭孢菌素市場：按劑型

  • 膠囊
  • 藥片
  • 其他劑型

第10章 全球頭孢菌素市場：依用途

  • 呼吸道感染疾病
  • 耳部感染疾病
  • 性行為感染傳染病
  • 皮膚感染疾病
  • 尿道感染
  • 其他用途

第11章全球頭孢菌素市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 居家護理
  • 其他最終用戶

第12章全球頭孢菌素市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第13章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第14章公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • AstraZeneca
  • Aurobindo Pharma
  • Johnson & Johnson Private Limited
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Currax Pharmaceuticals LLC
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Aristo Pharmaceuticals Ltd
  • Baxter International
  • Lupin Pharmaceuticals Inc.
  • Mankind Pharma
  • Macleods Pharmaceuticals Ltd
Product Code: SMRC24026

According to Stratistics MRC, the Global Cephalosporin Market is accounted for $16.00 billion in 2023 and is expected to reach $22.97 billion by 2030 growing at a CAGR of 5.3% during the forecast period. Cephalosporin is a bactericidal, broad-spectrum, B-lactam antibiotic that was originally developed from the fungus Acremonium. It is used to treat bacterial diseases such as tonsillitis, bronchitis, otitis media, gonorrhoea, and pneumonia, as well as skin infections, strep throat, staph infections, and others. It inhibits enzymes in the cell wall of the susceptible bacteria and disrupts cell synthesis. Cephalosporin is primarily designated for prophylaxis as well as the treatment of infections caused by bacteria.

According to the 2017 Global Impact of Respiratory Disease report, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for approximately 4 million deaths each year. In addition, pneumonia killed 920,136 children under the age of five in 2015, accounting for 15% of all deaths in this age group. Streptococcus pneumonia is still the most common bacterial cause of pneumonia in children under the age of five, affecting 393,000 children in 2015.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

Cephalosporins are a class of antibiotics that are widely used to treat a variety of bacterial infections. The increase in infectious diseases can be attributed to various factors. One of the main drivers is the emergence of drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria. These resistant strains are more difficult to treat with traditional antibiotics, leading to a higher demand for cephalosporins, which are still effective against many of these bacteria. Additionally, factors such as population growth, urbanisation, and increased travel have contributed to the spread of infectious diseases. As more people live in close proximity to each other and travel frequently, the risk of infection transmission is heightened. This has led to a competitive market landscape, with a wide range of cephalosporin products available to healthcare providers.

Restraint:

High cost

The high cost of cephalosporin antibiotics poses a significant restraint on the market. Cephalosporins are often priced at a premium due to the complex manufacturing processes involved, research and development expenses, and the need for stringent quality control measures. These higher costs can limit access to these vital antibiotics, especially in low-income regions or areas with limited healthcare budgets. Additionally, the high cost of cephalosporins can put a strain on healthcare systems and lead to increased healthcare expenditures. Thus, this factor is hampering market growth.

Opportunity:

Increasing applications in various medical sectors

Expanding applications of cephalosporins beyond their traditional uses presents a significant opportunity in various medical sectors. Cephalosporins, known for their antimicrobial properties, are finding increased utility in diverse domains, including veterinary medicine, agriculture, and non-clinical settings. In veterinary medicine, cephalosporins are used to treat bacterial infections in animals, addressing concerns about animal health and the potential transfer of antibiotic-resistant bacteria to humans. In agriculture, cephalosporins are being explored for their potential to prevent and treat bacterial infections in crops and livestock. These applications aim to improve agricultural productivity and ensure food safety by controlling bacterial diseases in plants and animals. Additionally, cephalosporins are being researched for non-clinical purposes, such as in microbial synthesis processes and laboratory research, showcasing the versatility of this antibiotic class beyond conventional therapeutic use. These different domains are propelling market expansion.

Threat:

Lack of skilled professionals

The cephalosporin market faces a significant threat due to a lack of skilled professionals. Cephalosporin antibiotics require expertise in their production, quality control, and administration. However, there is a shortage of professionals with the necessary skills and knowledge to handle these tasks. This shortage can impact the overall productivity and efficiency of the market, leading to potential delays in drug development, manufacturing, and distribution. Additionally, it may limit the capacity to meet the growing demand for cephalosporin antibiotics, especially in regions where the prevalence of infectious diseases is high. Therefore, it is a significant barrier to market demand.

COVID-19 Impact

The COVID-19 virus outbreak has had a significant negative influence on the cephalosporin market. Lockdowns, travel restrictions, and business closures brought on by COVID-19 have had an impact on the economies and sectors of numerous nations. The closing of numerous plants and factories has had a detrimental influence on the production, delivery schedules, and sales of goods on the international market. A few businesses have already warned of potential delivery delays and declines in future product sales. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths.

The Respiratory Tract Infection segment is expected to be the largest during the forecast period

The Respiratory Tract Infection (RTI) segment is estimated to hold the largest share, owing to the increasing prevalence of respiratory infections globally. Cephalosporins, a class of antibiotics, are widely prescribed for treating RTIs, including pneumonia, bronchitis, and sinusitis. Their effectiveness against a broad spectrum of bacteria, including common respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae, makes them a primary choice for clinicians. Additionally, the emergence of drug-resistant bacterial strains further emphasises the importance of cephalosporins in managing these infections. This ongoing effort is expected to sustain the growth of the RTI segment

The First-generation Cephalosporin segment is expected to have the highest CAGR during the forecast period

The First-generation Cephalosporin segment is anticipated to have lucrative growth during the forecast period. These antibiotics belong to the earliest generation of cephalosporins and have a broad spectrum of activity against gramme-positive bacteria, including staphylococci and streptococci. They are often used to treat common infections like skin and soft tissue infections, urinary tract infections, and respiratory tract infections. Moreover, healthcare professionals value first-generation cephalosporins for their efficacy, relatively low cost, and proven safety profile. Their longstanding presence in the market and established track record make them a trusted choice, especially for uncomplicated infections. Therefore, there is an increasing demand for segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a vital player in the global cephalosporin market. Cephalosporins, being a crucial class of antibiotics, are widely used in the region for treating various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. Furthermore, countries like China, India, Japan, South Korea, and others in Southeast Asia have a well-established pharmaceutical industry and are actively involved in research and development to innovate and produce cephalosporin drugs efficiently. The region's economic growth and increasing healthcare expenditure further drive the demand for cephalosporin antibiotics, ensuring a robust and promising market outlook.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The North American region holds a prominent position in the global cephalosporin market, being a key hub for pharmaceutical advancements and healthcare infrastructure. The market's growth is propelled by factors such as the increasing prevalence of bacterial infections, a growing elderly population prone to infections, and a high demand for efficient healthcare solutions. Furthermore, countries like the United States and Canada drive the cephalosporin market in North America. These nations have well-established pharmaceutical manufacturing capabilities and robust research and development efforts aimed at innovation and drug discovery.

Key players in the market

Some of the key players in the Cephalosporin Market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Aurobindo Pharma, Johnson & Johnson Private Limited, Cipla Inc., Sun Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Aristo Pharmaceuticals Ltd, Baxter International, Lupin Pharmaceuticals Inc., Mankind Pharma and Macleods Pharmaceuticals Ltd.

Key Developments:

In September 2023, Major Cipla has announced that it acquires South Africa wholly-owned subsidiary of the Mumbai-based drug major, has inked a binding term sheet with Actor Holdings (Pty) Ltd to acquire 100 per cent of the issued ordinary shares of Actor Pharma, the drug major said in a regulatory filing. This development underpins Cipla's commitment and investment in its over-the- counter (OTC) business and supports its journey to be a leading healthcare player in South Africa.

In April 2023, Cipla signs pact with Novartis Pharma AG for diabetes drug Galvus. The perpetual license agreement is to manufacture and market the drug and its combination brands from January 2026. The agreement is subject to satisfaction of certain conditions precedent. During the interim Cipla will continue to market and distribute Galvus branded products. This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category.

Generations Covered:

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin

Types Covered:

  • Branded
  • Generic

Route of Administrations Covered:

  • Intravenous
  • Oral

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Dosage Forms Covered:

  • Capsules
  • Tablets
  • Other Dosage Forms

Applications Covered:

  • Respiratory Tract Infection
  • Ear Infection
  • Sexually Transmitted Infection
  • Skin Infection
  • Urinary Tract Infection
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cephalosporin Market, By Generation

  • 5.1 Introduction
  • 5.2 First-generation Cephalosporin
  • 5.3 Second-generation Cephalosporin
  • 5.4 Third-generation Cephalosporin
  • 5.5 Fourth-generation Cephalosporin
  • 5.6 Fifth-generation Cephalosporin

6 Global Cephalosporin Market, By Type

  • 6.1 Introduction
  • 6.2 Branded
  • 6.3 Generic

7 Global Cephalosporin Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous
  • 7.3 Oral

8 Global Cephalosporin Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Online Pharmacy

9 Global Cephalosporin Market, By Dosage Form

  • 9.1 Introduction
  • 9.2 Capsules
  • 9.3 Tablets
  • 9.4 Other Dosage Forms

10 Global Cephalosporin Market, By Application

  • 10.1 Introduction
  • 10.2 Respiratory Tract Infection
  • 10.3 Ear Infection
  • 10.4 Sexually Transmitted Infection
  • 10.5 Skin Infection
  • 10.6 Urinary Tract Infection
  • 10.7 Other Applications

11 Global Cephalosporin Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Specialty Clinics
  • 11.4 Homecare
  • 11.5 Other End Users

12 Global Cephalosporin Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 F. Hoffmann-La Roche Ltd.
  • 14.2 Teva Pharmaceutical Industries Ltd.
  • 14.3 Mylan N.V.
  • 14.4 Pfizer Inc.
  • 14.5 Novartis AG
  • 14.6 GlaxoSmithKline plc
  • 14.7 Merck & Co., Inc.
  • 14.8 AstraZeneca
  • 14.9 Aurobindo Pharma
  • 14.10 Johnson & Johnson Private Limited
  • 14.11 Cipla Inc.
  • 14.12 Sun Pharmaceutical Industries Ltd.
  • 14.13 Currax Pharmaceuticals LLC
  • 14.14 Novo Nordisk A/S
  • 14.15 Takeda Pharmaceutical Company Limited
  • 14.16 Aristo Pharmaceuticals Ltd
  • 14.17 Baxter International
  • 14.18 Lupin Pharmaceuticals Inc.
  • 14.19 Mankind Pharma
  • 14.20 Macleods Pharmaceuticals Ltd

List of Tables

  • Table 1 Global Cephalosporin Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cephalosporin Market Outlook, By Generation (2021-2030) ($MN)
  • Table 3 Global Cephalosporin Market Outlook, By First-generation Cephalosporin (2021-2030) ($MN)
  • Table 4 Global Cephalosporin Market Outlook, By Second-generation Cephalosporin (2021-2030) ($MN)
  • Table 5 Global Cephalosporin Market Outlook, By Third-generation Cephalosporin (2021-2030) ($MN)
  • Table 6 Global Cephalosporin Market Outlook, By Fourth-generation Cephalosporin (2021-2030) ($MN)
  • Table 7 Global Cephalosporin Market Outlook, By Fifth-generation Cephalosporin (2021-2030) ($MN)
  • Table 8 Global Cephalosporin Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Cephalosporin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 10 Global Cephalosporin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 11 Global Cephalosporin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 12 Global Cephalosporin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 13 Global Cephalosporin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 14 Global Cephalosporin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 15 Global Cephalosporin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 16 Global Cephalosporin Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 17 Global Cephalosporin Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 18 Global Cephalosporin Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 19 Global Cephalosporin Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 20 Global Cephalosporin Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 21 Global Cephalosporin Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 22 Global Cephalosporin Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Cephalosporin Market Outlook, By Respiratory Tract Infection (2021-2030) ($MN)
  • Table 24 Global Cephalosporin Market Outlook, By Ear Infection (2021-2030) ($MN)
  • Table 25 Global Cephalosporin Market Outlook, By Sexually Transmitted Infection (2021-2030) ($MN)
  • Table 26 Global Cephalosporin Market Outlook, By Skin Infection (2021-2030) ($MN)
  • Table 27 Global Cephalosporin Market Outlook, By Urinary Tract Infection (2021-2030) ($MN)
  • Table 28 Global Cephalosporin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Global Cephalosporin Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Cephalosporin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 Global Cephalosporin Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 32 Global Cephalosporin Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 33 Global Cephalosporin Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.